Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Datavault AI's $2.0B structured financing term sheet could give the company a collateral base and global tokenization mandate, but the deal is non-binding, potentially dilutive, and loaded with proof gates.
OpenA filing-led Datavault AI Q1 2026 earnings thesis focused on recognized revenue, tokenization contracts, cash conversion, losses, liquidity, and dilution risk.
OpenA product-level DVLT diligence addendum that maps VerifyU, ADIO, Datavault, IDE, RWA, and NILX against audited revenue proof, cash conversion, and customer validation.
OpenDatavault AI's Perpetuals.com agreement gives its RWA tokenization story a needed liquidity layer, but the investment case still depends on listings, trading volume, fee recognition, and cash collection.
OpenA source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenA filing-led diligence review of Datavault AI, focused on revenue quality, cash conversion, dilution, tokenization claims, GPU deployment proof, and validation gates.
OpenA highly bullish but source-gated Datavault AI analysis framing DVLT as a speculative public option on AI data ownership, tokenization, SanQtum edge infrastructure, CyberCatch optionality, and contract-to-cash proof gates.
OpenAEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenAddex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenAchieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.
OpenAcumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.
Open